IsoPlexis' IsoCode Chip, its next-generation technology capable of identifying and predicting patient responses to immunotherapy, was recognized as the top innovation of 2017 by The Scientist. IsoPlexis’ single-cell technology was recognized as a detection system poised to revolutionize clinical research and advance scientific knowledge. The Scientist’s jury member Cruickshaw-Quinn stated: “The IsoLight single-cell technology, with its ease-of-use, has the potential to impact cancer research for both biomarker discovery and patient monitoring.”